Autel to Showcase Breakthrough EV Charging Innovations at ICNC23
29.8.2023 12:21:00 EEST | Business Wire | Press release
Autel Energy, a leading provider of innovative EV charging solutions, is pleased to announce its participation in the highly-anticipated Intercharge Network Conference 2023 (ICNC23) to be held on August 29-31, 2023, in Berlin. Ting Cai, CEO of Autel Europe, is set to captivate the audience with an insightful speech on the future of EV charging. Autel's hallmark innovation, the MaxiCharger DC Compact, will take center stage as it makes a live demonstration at the Plug&Charge Showcase Zone to showcase its seamless charging process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230828771064/en/
Complete MaxiCharger Lineup Unveiled at ICNC23 and IAA MOBILITY 2023 (Graphic: Business Wire)
ICNC23 is renowned for bringing together top industry professionals, experts, and stakeholders in the electric vehicle charging infrastructure domain. Ting Cai’s speech and Autel’s charging capabilities of its products will provide attendees with an exclusive opportunity to experience first-hand the cutting-edge technology that Autel Energy has brought to the market.
Autel MaxiCharger series offer a revolutionary charging solution that has transformed the charging experience for electric vehicle owners. With its high-speed charging capabilities, intuitive user interface, and compatibility with various electric vehicle models, Autel has earned its reputation as an indispensable tool for EV owners. Notably, Autel Energy has been officially checked and validated by Hubject, making its way into the Plug&Charge ecosystem. At ICNC23, Autel will bring its MaxiCharger DC Compact to demonstrate the charging process at the Plug&Charge Showcase Zone, which will impeccably showcase its exceptional features, emphasizing its role in providing a seamless and efficient charging process for electric vehicles.
Following the ICNC23, Autel Energy is excited to continue its engagement with the electric vehicle community at IAA MOBILITY 2023 (International Motor Show Germany) to take place on September 5-10, 2023, in Munich. During this period, Autel will embark on a roadshow, with its event vehicles journeying from ICNC in Berlin all the way to IAA MOBILITY in Munich and ultimately welcoming visitors at booth C2 A31.
"We are delighted to be part of ICNC23 and IAA MOBILITY 2023, where we can showcase the capabilities of Autel’s EV chargers and its seamless integration with various EV models," said Ting Cai, CEO of Autel Europe. "As the EV market continues to grow, Autel Energy remains committed to delivering cutting-edge charging solutions that enhance the driving experience for EV owners worldwide."
Visitors attending ICNC23 and IAA MOBILITY will have the exclusive opportunity to explore the charging process of the demonstration EV by Autel Energy's comprehensive array of EV charging products. Autel Energy's team of experts will be available at the event to engage with visitors, share insights, and discuss the transformative potential of their cutting-edge charging solutions.
For more information about Autel Energy and its EV charging solutions, please visit: https://autelenergy.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828771064/en/
Contact information
Jiaqi Liu
Email:jiaqi.liu@autel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom